LinkedIn Post — PyrAmes Inc. is proud to announce that it has been granted Breakthrough Device Designation (BDD) from the FDA for Boppli, our novel continuous, non-invasive blood pressure (cNIBP) monitoring system intended for use in neonatal critical care settings. The FDA’s BDD program is intended to facilitate development and expedite review of breakthrough medical device technologies. Breakthrough Device Designation has the potential to accelerate our plans to bring Boppli to market to improve medical care for babies in need of better blood pressure monitoring. For more information, visit www.pyrameshealth.com
